

ASCERTAIN CONSORTIUM MEETS IN BRUSSELS TO ADVANCE FINAL PROJECT PHASE

Brussels, 14. April 2026 – The ASCERTAIN consortium convened in Brussels for a two-day meeting, marking the transition into the final phase of the project. Bringing together partners from across Europe, the meeting provided a key opportunity to align on priorities, strengthen collaboration, and prepare for the project's final months.

The first day focused on internal coordination, with partners working intensively on cross-model interactions and the validation of ASCERTAIN's three use cases: personalised cancer medicines, CAR T-cell therapies, and Next Generation Sequencing. Discussions also explored how to better integrate environmental impact considerations into both the models and the Policy Support Tool. In addition, partners began shaping the programme and key messages for the upcoming final conference, ensuring a strong and coherent conclusion to the project.

On the second day, ASCERTAIN welcomed a diverse group of external stakeholders, including representatives from policy, academia, and healthcare. Through interactive workshops and scenario-based exercises, participants engaged directly with the project's models and Policy Support Tool. By testing different user perspectives and decision-making pathways, stakeholders explored how the tools can support real-world policy and reimbursement decisions.

The sessions focused on cross-model scenario testing, validation of the three use cases, and reflection on the practical relevance and usability of the platform. Stakeholders provided valuable feedback on how the models can be applied in practice, their potential for adoption, and how their value can be communicated to wider audiences.

The meeting highlighted the importance of collaboration between technical experts and end users to ensure that ASCERTAIN's outputs are both scientifically robust and practically relevant.

The consortium now looks ahead to the ASCERTAIN Final Conference, which will take place in October 2026 in Brussels, where key results and policy recommendations will be presented.

For more information, visit www.access2meds.eu. About ASCERTAIN: www.access2meds.eu

Press contact

Name: Prof.dr Carin Uyl-de Groot

Position: Professor of Health Technology Assessment and Director of the Institute for Medical Technology Assessment (iMTA), Project coordinator of the Horizon Europe project ASCERTAIN Erasmus School of Health Policy & Management (ESHPM)

Erasmus University of Rotterdam

E-Mail: uyl@eshpm.eur.nl